March 23 (Reuters) – Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm’s experimental treatment for several autoimmune diseases.
Here are the details:
(Reporting by Siddhi Mahatole and Kunal Das in Bengaluru)
